TRANEXAMIC ACID TABLETS

देश: कनाडा

भाषा: अंग्रेज़ी

स्रोत: Health Canada

इसे खरीदें

सक्रिय संघटक:

TRANEXAMIC ACID

थमां उपलब्ध:

STERIMAX INC

ए.टी.सी कोड:

B02AA02

INN (इंटरनेशनल नाम):

TRANEXAMIC ACID

डोज़:

500MG

फार्मास्यूटिकल फॉर्म:

TABLET

रचना:

TRANEXAMIC ACID 500MG

प्रशासन का मार्ग:

ORAL

पैकेज में यूनिट:

10

प्रिस्क्रिप्शन प्रकार:

Prescription

चिकित्सीय क्षेत्र:

HEMOSTATICS

उत्पाद समीक्षा:

Active ingredient group (AIG) number: 0114760001; AHFS:

प्राधिकरण का दर्जा:

APPROVED

प्राधिकरण की तारीख:

2013-01-31

उत्पाद विशेषताएं

                                Tranexamic Acid Tablets (Tranexamic Acid Tablets)
Page 1 of 24
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TRANEXAMIC ACID TABLETS
(Tranexamic Acid Tablets)
Tablet, 500 mg, Oral
Mfr. Std
Antifibrinolytic Agent
Submission Control No.: 260438
SteriMax Inc.
2770 Portland Drive
Oakville, ON
L6H 6R4
Date of Initial Authorization:
December 3, 2015
Date of Revision:
July 5, 2022
Tranexamic Acid Tablets (Tranexamic Acid Tablets)
Page 2 of 24
RECENT MAJOR LABEL CHANGES
2 CONTRAINDICATIONS
07/2022
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
07/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.................................................................................................
2
TABLE OF CONTENTS
......................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................................
4
1
INDICATIONS
..................................................................................................................
4
1.1
Pediatrics
..................................................................................................................
4
1.2
Geriatrics...................................................................................................................
4
2
CONTRAINDICATIONS......................................................................................................
4
4
DOSAGE AND ADMINISTRATION
.......................................................................................
5
4.1
Dosing Considerations
...............................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment.............................................................
5
4.5
Missed Dose
.................................................................................................
                                
                                पूरा दस्तावेज़ पढ़ें
                                
                            

अन्य भाषाओं में दस्तावेज़

उत्पाद विशेषताएं उत्पाद विशेषताएं फ़्रेंच 05-07-2022

इस उत्पाद से संबंधित अलर्ट देखें

दस्तावेज़ इतिहास देखें